{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vasculitis",
    "query": {
      "condition": "Vasculitis"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 207,
    "total_pages": 21,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vasculitis&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T05:36:46.269Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07105228",
      "title": "Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Retinal Vasculitis"
      ],
      "interventions": [
        {
          "name": "aflibercept 2mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 290000,
      "start_date": "2025-07-15",
      "completion_date": "2025-09-15",
      "has_results": false,
      "last_update_posted_date": "2025-10-10",
      "last_synced_at": "2026-05-22T05:36:46.269Z",
      "location_count": 1,
      "location_summary": "Tarrytown, New York",
      "locations": [
        {
          "city": "Tarrytown",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07105228"
    },
    {
      "nct_id": "NCT01613599",
      "title": "An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Granulomatosis With Polyangiitis",
        "Microscopic Polyangiitis"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2012-06-20",
      "completion_date": "2017-04-28",
      "has_results": true,
      "last_update_posted_date": "2018-07-26",
      "last_synced_at": "2026-05-22T05:36:46.269Z",
      "location_count": 15,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 11 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01613599"
    },
    {
      "nct_id": "NCT03906227",
      "title": "Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in ANCA Vasculitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "ANCA Associated Vasculitis"
      ],
      "interventions": [
        {
          "name": "ENUMERATION OF CD5+ B Cells",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 9,
      "start_date": "2019-06-28",
      "completion_date": "2025-02-27",
      "has_results": true,
      "last_update_posted_date": "2025-11-26",
      "last_synced_at": "2026-05-22T05:36:46.269Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03906227"
    },
    {
      "nct_id": "NCT02190929",
      "title": "Educational Needs of Patients With Systemic Vasculitis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Behcet's Disease",
        "Churg-Strauss Syndrome",
        "Vasculitis, Central Nervous System",
        "Giant Cell Arteritis",
        "Wegener Granulomatosis",
        "Henoch-Schoenlein Purpura",
        "Microscopic Polyangiitis",
        "Polyarteritis Nodosa",
        "Takayasu's Arteritis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 386,
      "start_date": "2012-03",
      "completion_date": "2014-02",
      "has_results": false,
      "last_update_posted_date": "2014-07-15",
      "last_synced_at": "2026-05-22T05:36:46.269Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02190929"
    },
    {
      "nct_id": "NCT05095844",
      "title": "National Vaccine Adverse Event Reporting Survey and Etiology",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "COVID-19",
        "Vaccine Adverse Reaction",
        "Vaccine Reaction",
        "Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use",
        "Corona Virus Infection",
        "Blood Clot",
        "Thrombocytopenia",
        "Neuritis",
        "Vasculitis",
        "Influenza",
        "Guillain-Barré",
        "GWAS",
        "Genetic Sequencing"
      ],
      "interventions": [
        {
          "name": "vaccinated",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Neuroganics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "5 Years to 99 Years"
      },
      "enrollment_count": 100000,
      "start_date": "2022-03-15",
      "completion_date": "2024-04-01",
      "has_results": false,
      "last_update_posted_date": "2022-03-18",
      "last_synced_at": "2026-05-22T05:36:46.269Z",
      "location_count": 1,
      "location_summary": "Northglenn, Colorado",
      "locations": [
        {
          "city": "Northglenn",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05095844"
    },
    {
      "nct_id": "NCT00001457",
      "title": "Lamivudine for Chronic Hepatitis B",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis B",
        "Chronic Hepatitis D",
        "Glomerulonephritis",
        "Polyarteritis Nodosa"
      ],
      "interventions": [
        {
          "name": "Lamivudine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 60,
      "start_date": "1995-09",
      "completion_date": "2005-09",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-05-22T05:36:46.269Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001457"
    },
    {
      "nct_id": "NCT07108387",
      "title": "Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Giant Cell Arteritis (GCA)"
      ],
      "interventions": [
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Discontinue Tocilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2025-12-11",
      "completion_date": "2030-01-11",
      "has_results": false,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-05-22T05:36:46.269Z",
      "location_count": 7,
      "location_summary": "Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 4 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Great Neck",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07108387"
    },
    {
      "nct_id": "NCT01917721",
      "title": "Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kawasaki Disease",
        "Coronary Aneurysm"
      ],
      "interventions": [
        {
          "name": "Doxycycline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hawaii Pacific Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Month to 21 Years"
      },
      "enrollment_count": 50,
      "start_date": "2013-10",
      "completion_date": "2026-08",
      "has_results": false,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-05-22T05:36:46.269Z",
      "location_count": 1,
      "location_summary": "Honolulu, Hawaii",
      "locations": [
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01917721"
    },
    {
      "nct_id": "NCT04919538",
      "title": "Longitudinal Study for Relapsing Polychondritis",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Relapsing Polychondritis",
        "Vasculitis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 100,
      "start_date": "2021-02-26",
      "completion_date": "2030-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-23",
      "last_synced_at": "2026-05-22T05:36:46.269Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04919538"
    },
    {
      "nct_id": "NCT00271570",
      "title": "Infliximab (Remicade) for Patients With Acute Kawasaki Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Kawasaki Disease"
      ],
      "interventions": [
        {
          "name": "Infliximab (Remicade)",
          "type": "DRUG"
        },
        {
          "name": "Intravenous immunoglobulin (IVIG)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "Up to 18 Years"
      },
      "enrollment_count": 24,
      "start_date": "2004-04",
      "completion_date": "2006-10",
      "has_results": true,
      "last_update_posted_date": "2010-06-14",
      "last_synced_at": "2026-05-22T05:36:46.269Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00271570"
    }
  ]
}